On September 3, SBP GROUP rose 3.33% in regular trading, trading at HK$5.42 per share, with turnover of HK$40.24 million. The rally was driven by a landmark clinical readout for its flagship ADC candidate TQB2102.

The company's subsidiary Chia Tai Tianqing announced that its independently developed HER2 biparatopic bispecific ADC, TQB2102 (rolditamig deuderuxtecan), achieved both the pre-specified primary endpoint and key secondary endpoint in an interim analysis of its Phase III trial for HER2-low recurrent or metastatic breast cancer. An independent data monitoring committee confirmed the results, making this the world's first successful Phase III study of a HER2 biparatopic bispecific ADC in the HER2-low breast cancer setting. The company has received written consent from China's CDE and plans to file a marketing application shortly.

The milestone adds to recent momentum. On August 31, the company granted Cipla exclusive rights to develop and commercialize TQB2102 across India, South Africa, and five other emerging markets, with potential milestone payments of up to $123 million plus tiered double-digit royalties. The company also repurchased 9 million shares on September 1 for approximately HK$47.43 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)